Markets:

Overview

News

Currencies

International

Treasuries

Dyadic International, Inc. - Common Stock (NQ:DYAI)

0.7650 +0.0351 (+4.81%)

Streaming Delayed Price Updated: 12:21 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dyadic International, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Dyadic to Present at World Vaccine Congress Washington 2023

March 30, 2023

From Dyadic International, Inc.

Via GlobeNewswire

Earnings Outlook For Dyadic International ↗

March 28, 2023

Via Benzinga

Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023

March 15, 2023

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

March 07, 2023

From Dyadic International, Inc.

Via GlobeNewswire

Recap: Dyadic International Q1 Earnings ↗

May 12, 2022

Dyadic International (NASDAQ:DYAI) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

India Funds Affordable COVID-19 Vaccine Candidate Using Dyadic's Platform ↗

April 13, 2022

Via Benzinga

Dyadic to Present at Roth Investor Conference and Upcoming Industry Events

March 01, 2023

From Dyadic International, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 10, 2023

Via Benzinga

Dyadic to Participate in Two Upcoming Investor Conferences

February 02, 2023

From Dyadic International, Inc.

Via GlobeNewswire

Why Phibro Shares Are Trading Higher Today? ↗

February 10, 2022

Phibro Animal Health Corp (NASDAQ: PAHC) and Dyadic International Inc (NASDAQ: DYAI) have entered into an

Via Benzinga

Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

January 24, 2023

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic Announces Sale of Equity Interest in Alphazyme

January 19, 2023

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference

January 04, 2023

Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA...

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal

December 14, 2022

From Dyadic International, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

December 05, 2022

During Monday's session, 49 companies made new 52-week lows.

Via Benzinga

Dyadic to Present at Upcoming Industry and Investor Events in November

November 07, 2022

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

October 27, 2022

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

October 27, 2022

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential

October 04, 2022

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic International: Q2 Earnings Insights ↗

August 10, 2022

Dyadic International (NASDAQ:DYAI) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Preview: Dyadic International ↗

August 09, 2022

Dyadic International (NASDAQ:DYAI) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement.

Via Benzinga

Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

July 27, 2022

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic International Earnings Perspective: Return On Capital Employed ↗

March 30, 2022

Dyadic International (NASDAQ:DYAI) brought in sales totaling $313.29 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 145.67%, resulting in a loss of $4.21...

Via Benzinga

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For March 29, 2022 ↗

March 29, 2022

Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.

Via Benzinga

A Preview Of Dyadic International's Earnings ↗

March 28, 2022

Dyadic International (NASDAQ:DYAI) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that Dyadic...

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

This Vaccine Stock Is Now On Janssen Pharmaceuticals, J&J, The White House's Radar ↗

January 04, 2022

Dyadic International shares were up over 6% on January 3rd. Shares are up over 35% in the last month.

Via Talk Markets

12 Health Care Stocks Moving In Friday's Intraday Session ↗

December 17, 2021

Gainers Genfit (NASDAQ:GN...

Via Benzinga

63 Biggest Movers From Friday ↗

December 20, 2021

Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.